01
Does the biological thesis hold up?
Examine the target, mechanism of action, disease rationale, and assumptions connecting the science to the proposed therapeutic effect.
For biotech and healthcare investors
Scientific Due Diligence for Biotech Investors
Independent scientific and commercial assessment of biotech assets before investment decisions.
Evaluate the biology, available evidence, competing programs, addressable market, and investment risks. Receive a decision-ready PowerPoint diligence deck and a presentation walkthrough.
Who this is for
- Biotech venture capital funds
- Healthcare investment funds
- Family offices investing in biotech
- Corporate venture investment teams
Experience supporting confidential single-asset decisions for multiple investment funds.
- oncology assets screened
- 1,200+
- asset deep dives
- 25+
- technical due diligence engagements
- 4+
- biochemistry and protein science
- PhD
The investment decision
Questions to answer before advancing a biotech investment.
Each engagement focuses on the scientific and commercial issues most likely to change the investment decision.
02
How strong is the available evidence?
Assess preclinical and clinical data, study design, translational relevance, and whether the evidence supports management's claims.
03
Is the asset meaningfully differentiated?
Compare the program with current care, competing assets, alternative mechanisms, and the broader therapeutic landscape.
04
What is the relevant market opportunity?
Estimate the addressable patient population and assess whether the proposed indication and competitive position support the investment thesis.
05
Which risks could change the decision?
Identify evidence gaps, weak assumptions, development uncertainties, and scientific red flags before additional capital is committed.
06
What should the investment team ask next?
Translate unresolved issues into focused management questions, additional diligence priorities, and clear investment committee discussion points.
Fixed-scope investor diligence
Choose the depth your investment decision requires.
Start with a focused asset screen, commission a detailed deep dive, or define a tailored technical due diligence engagement.
1–2 consulting days
High-Level Review
€2,000
Fixed project fee
A focused scientific screen for deciding whether a biotech asset merits deeper investigation.
- Scientific thesis and mechanism assessment
- Review of available public or company-provided evidence
- High-level competitive and market context
- Principal uncertainties and scientific red flags
- Concise PowerPoint diligence deck
- Presentation walkthrough with the investment team
5–7 consulting days
Deep Dive
€10,000
Fixed project fee
A detailed scientific and commercial assessment for an active single-asset investment decision.
- Detailed biological and mechanistic assessment
- Preclinical and clinical evidence review
- Competitive landscape and asset differentiation
- Addressable patient population and market sizing
- Evidence gaps and management diligence questions
- Detailed PowerPoint diligence deck and walkthrough
7+ consulting days
Technical Due Diligence
Request quote
Scope and fee agreed in advance
A tailored technical assessment for complex investment opportunities and confidential data-room reviews.
- In-depth scientific, technical, and development review
- Assessment of confidential datasets and company materials
- Detailed competitor mapping and differentiation analysis
- Tailored market sizing and investment-thesis assessment
- Management or external expert interviews when agreed
- Comprehensive PowerPoint diligence deck and walkthrough
Fixed fees exclude applicable VAT. Technical due diligence and optional expert interviews are scoped before work begins.
Your diligence deliverable
A diligence deck built for the investment discussion.
Each engagement includes a structured PowerPoint diligence deck and a presentation walkthrough with the investment team.
Public sources and confidential company materials
Investor-ready PowerPoint presentation
Independent review of risks and assumptions
Typical diligence deck structure
- 01Investment question and asset overview
- 02Target biology, mechanism, and therapeutic rationale
- 03Preclinical evidence and clinical findings
- 04Competing programs and asset differentiation
- 05Addressable patient population and market size
- 06Development assumptions, evidence gaps, and red flags
- 07Management questions and remaining diligence priorities
- 08Implications for the investment thesis
Relevant diligence experience
Experience across asset screening, portfolio review, and investor diligence.
Scientific training, systematic asset assessment, and commercial judgment support a clear view of the investment decision.
Asset screening and licensing
1,200+ oncology assets
Oncology asset screen for a confidential EU biotech
A structured review of preclinical and early clinical oncology assets progressed from database screening to prioritization, asset deep dives, and due diligence materials.
Portfolio assessment
Two engagements
Radiopharmaceutical portfolio assessment for a confidential US biotech
Clinical and preclinical programs were assessed against consistent criteria covering scientific rationale, development position, differentiation, and strategic fit.
Biotech investment decisions
Multiple investment funds
Confidential single-asset assessments for investment funds
Independent scientific assessment supported confidential decisions on individual biotech assets. Fund identities, asset names, and transaction details remain confidential.
Client identities, asset names, and transaction details remain confidential.
Engagement scope
Practical questions about investor diligence.
Reviews are tailored to the asset, available information, and the decision facing the investment team.
Which investors is the service designed for?
Biotech venture capital funds, healthcare investment funds, family offices investing in biotech, and corporate venture teams that need independent scientific support for a specific investment decision.
Which therapeutic areas, modalities, and development stages are covered?
Engagements can cover different therapeutic areas, treatment modalities, and development stages. The review is tailored to the individual asset, available evidence, and the investor's decision.
Can the assessment include confidential company materials?
Yes. Reviews can use public scientific and competitive information, company-provided documents, confidential datasets, and data-room materials. Confidential information is handled under the agreed terms.
Can management or external experts be interviewed?
Management interviews and discussions with clinicians or other external specialists can be included when agreed as part of the engagement scope.
What does the investment team receive?
Each engagement includes a PowerPoint diligence deck and a presentation walkthrough. The level of detail follows the selected review, asset complexity, and available evidence.
What falls outside the scope?
Medical devices, legal review, manufacturing due diligence, drug pricing, reimbursement assessments, and revenue forecasts are outside the scope of this service.
Discuss a specific investment
Bring the asset, the investment question, and the decision timeline.
We can define the appropriate review depth, available evidence, and diligence deliverable in an initial call.